Title
Corticosteroid vs. Amniotic Fluid Injections in Patients With Trigger Finger
Injection With Amniotic Fluid Versus Corticosteroid in Patients With Stenosing Tenosynovitis: a Randomized, Blinded Trial
Phase
Phase 3Lead Sponsor
J&M ShulerStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Stenosing TenosynovitisIntervention/Treatment
Amniotic fluid injection ...Study Participants
100The proposed study aims to investigate whether amniotic fluid injections are a better alternative to corticosteroid injections as a conservative treatment for stenosing tenosynovitis. Based on results from our most recent pilot study exploring patient outcomes after receiving an amnion injection, we were able to observe symptom resolution in more than half of the study population. Adverse events were extremely rare and not related to study participation. Given the numerous occurrences of successful symptom resolution, the next step is to compare patient outcomes to those of patients who receive the standard steroid injection. This study will compare outcome measurements of patients who receive amnion injections to those who receive steroid injections.
Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.
Solu-medrol
1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
Inclusion Criteria: Patient is at least 18 years of age Patient is diagnosed with stenosing tenosynovitis Exclusion Criteria: Patient is less than 18 years of age Pregnancy Enrolling clinician does not believe that the patient is mentally capable of understanding the research nature of the procedure due to mental handicap/disability or illiteracy.